<DOC>
	<DOC>NCT00319020</DOC>
	<brief_summary>The main objective of the FUTURE-2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE-1 study.</brief_summary>
	<brief_title>Bosentan in Children With Pulmonary Arterial Hypertension Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent by the parents or the legal representatives. Patients who completed the FUTURE 1 study. Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of FUTURE 1. Males or females &gt;= 2 and &lt; 12 years of age at enrollment in FUTURE 2 (this study). Females who are menstruating must have a negative pregnancy test. A reliable method of contraception must be considered, if appropriate. Intolerance to bosentan despite dose reductions. Any clinically significant laboratory abnormality that precludes continuation of bosentan therapy. Pregnancy or breastfeeding. Known hypersensitivity to bosentan or any of the excipients. Premature and permanent study drug discontinuation during FUTURE 1.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>bosentan</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>children</keyword>
	<keyword>FUTURE 1</keyword>
</DOC>